Renub Research

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

Press Release   •   Jul 29, 2013 07:14 EDT

Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care. Renub Research study titled “Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters. A. Hepatitis C Drugs Market & Forecast (Chapter 2) B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3) C. Hepatitis C Deals & Acquisitions (Chapter 4) D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5) E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6) F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7) Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)  1. Pegasys 2. Pegintron 3. Incivek 4. Victrelis Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)  1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)2. Faldaprevir (BI 201335) (Company: Boerhinger Ingelheim)3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)7. BI-207127 (Company: Boerhinger Ingelheim)8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)9. ABT-267 (Company: Abbott Laboratories)10. ABT-072/333 (Company: Abbott Laboratories)11. Alisporivir (Company: Novartis) Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)  1. Mericitabine (RG-7128) (Company: Roche)2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)3. GS-9256 (Company: Gilead Sciences)4. GS-9451 (Company: Gilead Sciences)5. MK-5172 (Company: Merck)6. Sovaprevir (ACH-1625) (Company: Achillion)7. IDX-320 (Company: Idenix)8. MK-8742 (Company: Merck)9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)10. IDX-719 (Company: Idenix)11. PPI-668 (Company: Presidio Pharmaceuticals)12. Setrobuvir (ANA-598) (Company: Roche)13. VX-222 (Company: Vertex Pharmaceuticals)14. GS-9669 (Company: Gilead Sciences)15. GS-9190 (Tegobuvir) (Company: Gilead Sciences)16. BMS-791325 (Company: Bristol-Myers Squibb) Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7) 1. Simeprevir (TMC 435) 2. Faldaprevir (BI 201335) (Boerhinger Ingelheim) 3. Asunaprevir (BMS-650032) 4. Sofosbuvir (PSI-7977 or GS-7977) 5. Daclatasvir (BMS-790052) 6. ABT-450/r (Ritonavir) 7. ABT-072/333 8. Alisporivir 9. Mericitabine (RG-7128)10. Danoprevir (RG7227) 11. GS-925612. Setrobuvir (ANA-598) 13. VX-222 14. GS-9190 (Tegobuvir)15. BMS-791325   Data Sources This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts. Primary sources include industry surveys and telephone interviews with industry experts.  Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases. 
Click here to view the report details:
Contact Us
Andy HillSr. Manager - Publisher RelationSales & Marketing Div.Renub ResearchEmail: Phone:  +1-678-302-0700 (USA) , +91-120-4219-822, +91-120-254-5750 (India)Web:

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.